Skip to main content
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience 3/2015

01.04.2015 | Original Paper

Pharmacotherapy of anxiety disorders in German-speaking countries: current status and changes between 1994 and 2011

verfasst von: Anna K. Holl, Renate Grohmann, Martin Letmaier, Annamaria Painold, Sabrina Mörkl, Sermin Toto, Siegfried Kasper

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Over the past years, international treatment guidelines have been established for the treatment of anxiety disorders. Nevertheless, little is known as to whether the actual inpatient treatment follows these guidelines. The main goal of this study was to answer the question whether patients with anxiety disorder are treated according to treatment guidelines. A total of 2,573 psychiatric inpatients with the diagnosis of anxiety disorder (920 men, 1,653 women) were identified on the basis of the data of the international drug safety programme in psychiatry AMSP. Of these patients, 25.3 % presented with phobia, 26.6 % with panic disorder, 18.7 % with generalized anxiety disorder (GAD), and 29.4 % with other diagnoses of anxiety. In all of the patients, 12.7 % did not receive any psychotropic medication and 22.9 % were not treated with antidepressants. Only 59.3 % of patients with GAD, 73.9 % of patients with panic disorder, and 52.1 % of patients with phobia were treated according to diagnostic guidelines. The majority (60.3 %) of all patients received one or two psychotropic drugs, and only 3.7 % received five or more psychotropic drugs. In two groups of patients (one group with phobia and one with panic disorder), the annual prescription rate of antidepressants significantly increased over time. The prescription rate for anticonvulsants in patients with GAD increased from 0 % in 1997 to 41.7 % in 2011, and for antipsychotics, from 40.7 % in 1997 to 47.2 % in 2011. In particular, patients with GAD were commonly treated with antipsychotics.
Literatur
1.
Zurück zum Zitat American Psychiatric Association (1998) Practice guidelines for the treatment of patients with panic disorder. Working group on panic disorder. American Psychiatric Association. Jack Gorman American Psychiatric Association (1998) Practice guidelines for the treatment of patients with panic disorder. Working group on panic disorder. American Psychiatric Association. Jack Gorman
2.
Zurück zum Zitat American Psychiatric Association (2010) Practice guidelines for the treatment of patients with panic disorders, 2nd edn. Working group on panic disorder. American Psychiatric Association. Laura J. Fochtmann American Psychiatric Association (2010) Practice guidelines for the treatment of patients with panic disorders, 2nd edn. Working group on panic disorder. American Psychiatric Association. Laura J. Fochtmann
3.
Zurück zum Zitat Baldwin DS, Waldman S, Allgulander C (2011) Evidence-based pharmacological treatment of generalized anxiety disorder. Int J Neuropsychopharmacol 14(5):697–710CrossRefPubMed Baldwin DS, Waldman S, Allgulander C (2011) Evidence-based pharmacological treatment of generalized anxiety disorder. Int J Neuropsychopharmacol 14(5):697–710CrossRefPubMed
4.
Zurück zum Zitat Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S et al (2010) Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 13(3):305–320CrossRefPubMed Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S et al (2010) Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 13(3):305–320CrossRefPubMed
5.
Zurück zum Zitat Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J et al (2012) Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract 16(2):77–84CrossRefPubMed Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J et al (2012) Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract 16(2):77–84CrossRefPubMed
6.
Zurück zum Zitat Bandelow B, Stein DJ, Dolberg OT, Andersen HF, Baldwin DS (2007) Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry 40(4):152–156CrossRefPubMed Bandelow B, Stein DJ, Dolberg OT, Andersen HF, Baldwin DS (2007) Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry 40(4):152–156CrossRefPubMed
8.
Zurück zum Zitat Bandelow B, Zohar J, Hollander E, Kasper S, Möller H-J, Allgulander C et al (2008) World federation of societies of biological psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders—first revision. World J Biol Psych 9(4):248–312CrossRef Bandelow B, Zohar J, Hollander E, Kasper S, Möller H-J, Allgulander C et al (2008) World federation of societies of biological psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders—first revision. World J Biol Psych 9(4):248–312CrossRef
9.
Zurück zum Zitat Beck AT, Steer RA, Sanderson WC, Skeie TM (1991) Panic disorder and suicidal ideation and behavior: discrepant findings in psychiatric outpatients. Am J Psychiatry 148(9):1195–1199CrossRefPubMed Beck AT, Steer RA, Sanderson WC, Skeie TM (1991) Panic disorder and suicidal ideation and behavior: discrepant findings in psychiatric outpatients. Am J Psychiatry 148(9):1195–1199CrossRefPubMed
10.
Zurück zum Zitat Bradwejn J, Ahokas A, Stein DJ, Salinas E, Emilien G, Whitaker T (2005) Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry 187:352–359CrossRefPubMed Bradwejn J, Ahokas A, Stein DJ, Salinas E, Emilien G, Whitaker T (2005) Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry 187:352–359CrossRefPubMed
11.
Zurück zum Zitat Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Therapeutics 23(8):1296–1310CrossRef Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Therapeutics 23(8):1296–1310CrossRef
12.
Zurück zum Zitat Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL (1989) How often is medication taken as prescribed? A novel assessment technique. J Am Med Assoc 261(22):3273–3277CrossRef Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL (1989) How often is medication taken as prescribed? A novel assessment technique. J Am Med Assoc 261(22):3273–3277CrossRef
13.
Zurück zum Zitat Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller H-J (2005) World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. World J Biol Psychiatry 6(3):132–191CrossRefPubMed Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller H-J (2005) World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. World J Biol Psychiatry 6(3):132–191CrossRefPubMed
14.
Zurück zum Zitat Friedman S, Jones JC, Chernen L, Barlow DH (1992) Suicidal ideation and suicide attempts among patients with panic disorder: a survey of two outpatient clinics. Am J Psychiatry 149(5):680–685CrossRefPubMed Friedman S, Jones JC, Chernen L, Barlow DH (1992) Suicidal ideation and suicide attempts among patients with panic disorder: a survey of two outpatient clinics. Am J Psychiatry 149(5):680–685CrossRefPubMed
15.
Zurück zum Zitat Furmark T, Appel L, Michelgård A, Wahlstedt K, Ahs F, Zancan S et al (2005) Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 58(2):132–142CrossRefPubMed Furmark T, Appel L, Michelgård A, Wahlstedt K, Ahs F, Zancan S et al (2005) Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 58(2):132–142CrossRefPubMed
16.
Zurück zum Zitat Gambi F, De Berardis D, Campanella D, Carano A, Sepede G, Salini G et al (2005) Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study. J Psychopharmacol 19(5):483–487CrossRefPubMed Gambi F, De Berardis D, Campanella D, Carano A, Sepede G, Salini G et al (2005) Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study. J Psychopharmacol 19(5):483–487CrossRefPubMed
17.
Zurück zum Zitat Grohmann R, Engel RR, Rüther E, Hippius H (2004) The AMSP drug safety program: methods and global results. Pharmacopsychiatry 37(Suppl 1):S4–S11PubMed Grohmann R, Engel RR, Rüther E, Hippius H (2004) The AMSP drug safety program: methods and global results. Pharmacopsychiatry 37(Suppl 1):S4–S11PubMed
18.
Zurück zum Zitat Hahn A, Lanzenberger R, Wadsak W, Spindelegger C, Moser U, Mien L-K et al (2010) Escitalopram enhances the association of serotonin-1A autoreceptors to heteroreceptors in anxiety disorders. J Neurosci 30(43):14482–14489CrossRefPubMed Hahn A, Lanzenberger R, Wadsak W, Spindelegger C, Moser U, Mien L-K et al (2010) Escitalopram enhances the association of serotonin-1A autoreceptors to heteroreceptors in anxiety disorders. J Neurosci 30(43):14482–14489CrossRefPubMed
19.
Zurück zum Zitat Kasper S, Brasser M, Schweizer E, Lyndon G, Prieto R (2014) How well do randomized controlled trial data generalize to “real-world” clinical practice settings? A comparison of two generalized anxiety disorder studies. Eur Neuropsychopharmacol 24(1):125–132CrossRefPubMed Kasper S, Brasser M, Schweizer E, Lyndon G, Prieto R (2014) How well do randomized controlled trial data generalize to “real-world” clinical practice settings? A comparison of two generalized anxiety disorder studies. Eur Neuropsychopharmacol 24(1):125–132CrossRefPubMed
20.
Zurück zum Zitat Kasper S, Herman B, Nivoli G, Van Ameringen M, Petralia A, Mandel FS et al (2014) Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol 24(2):87–96CrossRef Kasper S, Herman B, Nivoli G, Van Ameringen M, Petralia A, Mandel FS et al (2014) Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol 24(2):87–96CrossRef
21.
Zurück zum Zitat Kasper S, Stein DJ, Loft H, Nil R (2005) Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 186:222–226CrossRefPubMed Kasper S, Stein DJ, Loft H, Nil R (2005) Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 186:222–226CrossRefPubMed
22.
Zurück zum Zitat Katona CL (2001) Psychotropics and drug interactions in the elderly patient. Int J Geriatr Psychiatry 16(Suppl 1):S86–S90CrossRefPubMed Katona CL (2001) Psychotropics and drug interactions in the elderly patient. Int J Geriatr Psychiatry 16(Suppl 1):S86–S90CrossRefPubMed
23.
Zurück zum Zitat Klein DF (1964) Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia 5:397–408CrossRefPubMed Klein DF (1964) Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia 5:397–408CrossRefPubMed
24.
Zurück zum Zitat Lepola UM, Wade AG, Leinonen EV, Koponen HJ, Frazer J, Sjödin I et al (1998) A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 59(10):528–534CrossRefPubMed Lepola UM, Wade AG, Leinonen EV, Koponen HJ, Frazer J, Sjödin I et al (1998) A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 59(10):528–534CrossRefPubMed
25.
Zurück zum Zitat Mezhebovsky I, Mägi K, She F, Datto C, Eriksson H (2013) Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. Int J Geriatr Psychiatry 28(6):615–625CrossRefPubMed Mezhebovsky I, Mägi K, She F, Datto C, Eriksson H (2013) Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. Int J Geriatr Psychiatry 28(6):615–625CrossRefPubMed
26.
Zurück zum Zitat Montgomery SA, Kasper S (2012) Clinical Medicine Insights : therapeutics pharmacotherapy Update: pregabalin in the treatment of generalized anxiety disorder. Clin Med Insights Therapeutics 2:189–202 Montgomery SA, Kasper S (2012) Clinical Medicine Insights : therapeutics pharmacotherapy Update: pregabalin in the treatment of generalized anxiety disorder. Clin Med Insights Therapeutics 2:189–202
28.
Zurück zum Zitat National Institute for Health and Clinical Excellence (2004) NICE clinical guideline, anxiety: management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. NHS, NICE Clinical Guieline 22 National Institute for Health and Clinical Excellence (2004) NICE clinical guideline, anxiety: management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. NHS, NICE Clinical Guieline 22
29.
Zurück zum Zitat National Institute for Health and Clinical Excellence (2011) NICE clinical guideline, generalized anxiety disorder and panic disorder (with or without agoraphobia) in adults. NHS, NICE Clinical Guideline 113 National Institute for Health and Clinical Excellence (2011) NICE clinical guideline, generalized anxiety disorder and panic disorder (with or without agoraphobia) in adults. NHS, NICE Clinical Guideline 113
30.
Zurück zum Zitat Pollack M, Mangano R, Entsuah R, Tzanis E, Simon NM, Zhang Y (2007) A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology 194(2):233–242CrossRefPubMed Pollack M, Mangano R, Entsuah R, Tzanis E, Simon NM, Zhang Y (2007) A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology 194(2):233–242CrossRefPubMed
31.
Zurück zum Zitat Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G et al (2007) A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety 24(1):1–14CrossRefPubMed Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G et al (2007) A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety 24(1):1–14CrossRefPubMed
32.
Zurück zum Zitat Pollack MH, Worthington JJ, Otto MW, Maki KM, Smoller JW, Manfro GG et al (1996) Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 32(4):667–670PubMed Pollack MH, Worthington JJ, Otto MW, Maki KM, Smoller JW, Manfro GG et al (1996) Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 32(4):667–670PubMed
33.
Zurück zum Zitat Ribeiro L, Busnello JV, Kauer-Sant’Anna M, Madruga M, Quevedo J, Busnello EA et al (2001) Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res 34(10):1303–1307CrossRefPubMed Ribeiro L, Busnello JV, Kauer-Sant’Anna M, Madruga M, Quevedo J, Busnello EA et al (2001) Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res 34(10):1303–1307CrossRefPubMed
34.
Zurück zum Zitat Samuel M, Zimovetz EA, Gabriel Z, Beard SM (2011) Efficacy and safety of treatments for refractory generalized anxiety disorder: a systematic review. Int Clin Psychopharmacol 26(2):63–68CrossRefPubMed Samuel M, Zimovetz EA, Gabriel Z, Beard SM (2011) Efficacy and safety of treatments for refractory generalized anxiety disorder: a systematic review. Int Clin Psychopharmacol 26(2):63–68CrossRefPubMed
35.
Zurück zum Zitat Sheehan DV, Svedsäter H, Locklear JC, Eriksson H (2013) Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with generalized anxiety disorder (GAD): data from a randomized-withdrawal, placebo-controlled maintenance study. J Affect Disord 151(3):906–913CrossRefPubMed Sheehan DV, Svedsäter H, Locklear JC, Eriksson H (2013) Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with generalized anxiety disorder (GAD): data from a randomized-withdrawal, placebo-controlled maintenance study. J Affect Disord 151(3):906–913CrossRefPubMed
36.
Zurück zum Zitat Spindelegger C, Lanzenberger R, Wadsak W, Mien LK, Stein P, Mitterhauser M et al (2009) Influence of escitalopram treatment on 5-HT 1A receptor binding in limbic regions in patients with anxiety disorders. Mol Psychiatry 14(11):1040–1050CrossRefPubMed Spindelegger C, Lanzenberger R, Wadsak W, Mien LK, Stein P, Mitterhauser M et al (2009) Influence of escitalopram treatment on 5-HT 1A receptor binding in limbic regions in patients with anxiety disorders. Mol Psychiatry 14(11):1040–1050CrossRefPubMed
37.
Zurück zum Zitat Stahl SM, Gergel I, Li D (2003) Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 64(11):1322–1327CrossRefPubMed Stahl SM, Gergel I, Li D (2003) Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 64(11):1322–1327CrossRefPubMed
38.
Zurück zum Zitat Vaishnavi S, Alamy S, Zhang W, Connor KM, Davidson JRT (2007) Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuro Psychopharmacol Biol Psychiatry 31(7):1464–1469CrossRef Vaishnavi S, Alamy S, Zhang W, Connor KM, Davidson JRT (2007) Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuro Psychopharmacol Biol Psychiatry 31(7):1464–1469CrossRef
39.
Zurück zum Zitat Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T (1997) The effect of citalopram in panic disorder. Br J Psychiatry 170:549–553CrossRefPubMed Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T (1997) The effect of citalopram in panic disorder. Br J Psychiatry 170:549–553CrossRefPubMed
40.
Zurück zum Zitat Waern M, Spak F, Sundh V (2002) Suicidal ideation in a female population sample. Relationship with depression, anxiety disorder and alcohol dependence/abuse. Eur Arch Psychiatry Clin Neurosci 252(2):81–85CrossRefPubMed Waern M, Spak F, Sundh V (2002) Suicidal ideation in a female population sample. Relationship with depression, anxiety disorder and alcohol dependence/abuse. Eur Arch Psychiatry Clin Neurosci 252(2):81–85CrossRefPubMed
41.
Zurück zum Zitat Weisberg RB, Beard C, Moitra E, Dyck I, Keller MB (2014) Adequacy of treatment received by primary care patients with anxiety disorders. Depress Anxiety 31(5):443–450CrossRefPubMedCentralPubMed Weisberg RB, Beard C, Moitra E, Dyck I, Keller MB (2014) Adequacy of treatment received by primary care patients with anxiety disorders. Depress Anxiety 31(5):443–450CrossRefPubMedCentralPubMed
42.
Zurück zum Zitat Weissman MM, Klerman GL, Markowitz JS, Ouellette R (1989) Suicidal ideation and suicide attempts in panic disorder and attacks. N Engl J Med 321(18):1209–1214CrossRefPubMed Weissman MM, Klerman GL, Markowitz JS, Ouellette R (1989) Suicidal ideation and suicide attempts in panic disorder and attacks. N Engl J Med 321(18):1209–1214CrossRefPubMed
43.
Zurück zum Zitat Wensel TM, Powe KW, Cates ME (2012) Pregabalin for the treatment of generalized anxiety disorder. Ann Pharmacother 46(3):424–429CrossRefPubMed Wensel TM, Powe KW, Cates ME (2012) Pregabalin for the treatment of generalized anxiety disorder. Ann Pharmacother 46(3):424–429CrossRefPubMed
44.
Zurück zum Zitat Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B et al (2011) The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21(9):655–679CrossRefPubMed Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B et al (2011) The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21(9):655–679CrossRefPubMed
45.
Zurück zum Zitat Zitrin CM (1983) Differential treatment of phobias: use of imipramine for panic attacks. J Behav Ther Exp Psychiatry 14(1):11–18CrossRefPubMed Zitrin CM (1983) Differential treatment of phobias: use of imipramine for panic attacks. J Behav Ther Exp Psychiatry 14(1):11–18CrossRefPubMed
Metadaten
Titel
Pharmacotherapy of anxiety disorders in German-speaking countries: current status and changes between 1994 and 2011
verfasst von
Anna K. Holl
Renate Grohmann
Martin Letmaier
Annamaria Painold
Sabrina Mörkl
Sermin Toto
Siegfried Kasper
Publikationsdatum
01.04.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 3/2015
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-014-0523-7

Weitere Artikel der Ausgabe 3/2015

European Archives of Psychiatry and Clinical Neuroscience 3/2015 Zur Ausgabe

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.